Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLEX vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA-approved: Treatment of neoplastic diseases (e.g., acute lymphoblastic leukemia, breast cancer, head and neck cancer, non-Hodgkin lymphoma, osteosarcoma),FDA-approved: Treatment of severe psoriasis (adult, recalcitrant, disabling),FDA-approved: Treatment of active rheumatoid arthritis (adult, severe, active) and polyarticular juvenile idiopathic arthritis,Off-label: Management of ectopic pregnancy,Off-label: Treatment of Crohn's disease,Off-label: Management of uveitis
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Methotrexate undergoes hepatic metabolism to polyglutamate metabolites which are retained in cells. It is partially metabolized by aldehyde oxidase and xanthine oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 50% bound to serum proteins, primarily albumin.
Approximately 85-90% bound to serum albumin.
Vd: 0.4-0.8 L/kg (total body water), indicating extensive tissue distribution; higher in pleural effusions or ascites.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability: dose-dependent, variable (20-80%, higher with low doses); IM: complete but slower absorption; IV: 100%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use or reduce dose by 75%.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For acute lymphoblastic leukemia: 12.5 mg/m2 orally once weekly; for juvenile idiopathic arthritis: 10-15 mg/m2 orally or subcutaneously once weekly. Maximum single dose: 20 mg.
Not established; safety and efficacy not determined in pediatric patients.
Start at lowest end of dosing range (e.g., 5-7.5 mg orally weekly for rheumatoid arthritis) due to increased risk of toxicity from reduced renal function and folate stores.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
FOLEX (methotrexate) may cause severe toxicity including death, especially with high doses. Severe reactions include myelosuppression, hepatotoxicity, pulmonary fibrosis, renal failure, and gastrointestinal ulceration. Must be used only by physicians experienced in antimetabolite therapy. Patients should be closely monitored for bone marrow, liver, and renal toxicity.
None.
Hepatotoxicity: Risk of acute and chronic liver injury, fibrosis, and cirrhosis, especially with prolonged use or pre-existing liver disease,Myelosuppression: Risk of severe pancytopenia, especially in renal impairment or with concurrent NSAIDs,Pulmonary toxicity: Acute or chronic interstitial pneumonitis, fibrosis,Renal toxicity: Acute renal failure due to precipitation of methotrexate in renal tubules, especially with high doses,Gastrointestinal toxicity: Ulceration, perforation, hemorrhage,Dermatologic reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Concurrent NSAIDs increase methotrexate toxicity
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to methotrexate or any component,Breastfeeding,Severe renal impairment (creatinine clearance <10 m L/min),Severe hepatic impairment (e.g., cirrhosis, active hepatitis),Pre-existing severe bone marrow depression (e.g., pancytopenia),Pregnancy (teratogenic and embryotoxic)
Hypersensitivity to AURLUMYN or any of its components.
Avoid alcohol completely; may increase hepatotoxicity. No specific food restrictions, but maintain adequate hydration. Avoid folic acid-rich foods (e.g., fortified cereals, legumes) if combining with leucovorin rescue in high-dose therapy due to potential interference. Take folic acid supplements at a different time than methotrexate if prescribed.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
FDA Pregnancy Category X. First trimester: High risk of miscarriage, neural tube defects, craniofacial anomalies, and limb defects. Second and third trimesters: Fetal growth restriction, skeletal abnormalities, functional deficits. Avoid use during pregnancy.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Contraindicated during breastfeeding. Methotrexate (active component) is excreted in breast milk with an M/P ratio of approximately 0.08; risk of infant accumulation due to long half-life. Do not breastfeed during therapy or for at least 1 week after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Pregnancy is a contraindication; no dose adjustments are recommended. If used inadvertently, immediate discontinuation and high-dose folic acid rescue. Pharmacokinetic changes in pregnancy (increased Vd and clearance) may require dose reduction if used for non-pregnant patients, but absolute contraindication overrides.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Folex (methotrexate) is a folate analog antimetabolite used in oncology and autoimmune diseases. Administer leucovorin rescue 24 hours after high-dose methotrexate to prevent severe toxicity. Monitor renal function and methotrexate levels closely. Avoid NSAIDs as they reduce renal clearance and increase toxicity. Hepatotoxicity and pulmonary fibrosis are serious adverse effects. Intrathecal administration requires preservative-free formulation.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take folic acid supplements as prescribed to reduce side effects unless on high-dose therapy with leucovorin rescue.,Avoid alcohol completely during treatment due to increased risk of liver damage.,Report any signs of infection, unusual bleeding, or shortness of breath immediately.,Drink plenty of fluids to help flush the drug from your kidneys unless otherwise instructed.,Do not take any over-the-counter medications, especially NSAIDs (like ibuprofen), without consulting your doctor.,Use effective contraception during and for at least 3 months after treatment for both men and women.,Follow your dosing schedule exactly; missed doses can reduce effectiveness or increase toxicity.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLEX vs AURLUMYN, answered by our medical review team.
FOLEX is a Antineoplastic Agent that works by Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLEX and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLEX is: 30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLEX and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLEX is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of miscarriage, neural tube defects, craniofacial anomalies, and limb defects. Second and third trimesters: Fetal growth restri. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.